The aim is to analyze the clinical outcomes of patients with extramedullary plasmacytoma
(EMP) and review the characteristics of this disease. We retrospectively reviewed the clinical …

The combination of bortezomib (Velcade, PS-341) and lenalidomide (Revlimid) for the
treatment of multiple myeloma was proved by USA Food and Drug Administration in 2006 …

Simple Summary Radiotherapy is essential for the management of symptomatic osteolytic
lesions in multiple myeloma but usually requires a combination with systemic therapy. This …

Simple Summary According to the current SLiM-CRAB-criteria, asymptomatic multiple
myeloma patients who show> 1 focal lesion in MRI are now upstaged to multiple myeloma …

Introduction Solitary extramedullary plasmacytomas (SEP) of the head and neck are rare
and pose unique challenges. This study aimed to explore the clinical spectrum and …

Extramedullary plasmacytoma of the head and neck is a rare indolent neoplasm.
Radiotherapy is often the preferred treatment option with excellent local control and survival …

Study Design Mutlidisciplinary consensus recommendations for patients suffering from
multiple myeloma (MM) involvement of the spinal column by the Spine Section of the …

Background Comprehensive studies on the prognosis of solitary bone plasmacytoma (SPB)
are lacking, especially in elderly patients with SPB. This study aims to establish a novel …

Objective: Definitive radiotherapy (RT) with or without surgery is the standard of care for
solitary plasmacytoma. Here, we report clinical outcomes for this rare malignant neoplasm …

Introduction. Solitary extramedullary plasmacytoma (SEP) is a rare neoplasm that is derived
from monoclonal proliferation of plasma cells in the soft tissues or organs arising outside the …